NasdaqGS:BNTXBiotechs
A Look At BioNTech (BNTX) Valuation After Expanded Oncology Pipeline Update
BioNTech (NasdaqGS:BNTX) has laid out an expanded oncology plan for 2026, centered on a broader late-stage pipeline, additional combination studies with large partners, and more Phase 3 trial initiations and data readouts.
See our latest analysis for BioNTech.
The oncology update lands after a strong near term run, with a 1 day share price return of 4.90% and 30 day share price return of 13.06%. However, the 1 year total shareholder return of a 4.66% decline and 3 year total shareholder...